Aurinia Pharmaceuticals : 2025 Corporate Presentation

Published: 2025-05-01 19:46:23 ET AUPH

Published on 05/01/2025 at 19:46

Corporate Presentation

May 2025

Changing the Trajectory of

Autoimmune Diseases

Continue LUPKYNIS commercial growth

Advance AUR200

development

commercialization

diagnosis and

3

LUPKYNIS

Net Product Sales

$250.0M

The first FDA-approved oral therapy for the treatment of lupus nephritis

$45.5M

2021 2022 2023 2024 2025

Guidance Range a

a Guidance as of February 27, 2025 4

About Lupus Nephritis

Disclaimer

Aurinia Pharmaceuticals Inc. published this content on May 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 01, 2025 at 23:45 UTC.